ebola
viru
ebov
caus
outbreak
highli
lethal
hemorrhag
fever
human
viru
transmit
direct
contact
well
aerosol
consid
potenti
bioweapon
direct
immun
respiratori
tract
particularli
effect
infect
mucos
surfac
previous
develop
intranas
vaccin
base
replicationcompet
human
parainfluenza
viru
type
express
ebov
glycoprotein
gp
show
immunogen
protect
high
dose
parenter
ebov
challeng
howev
adult
human
popul
consider
immun
common
human
pathogen
replic
immunogen
vaccin
popul
might
greatli
restrict
inde
present
studi
replic
vaccin
respiratori
tract
guinea
pig
found
restrict
undetect
level
restrict
appear
base
neutral
antibodi
cellular
compon
immun
surprisingli
even
though
replic
highli
restrict
anim
induc
high
level
ebovspecif
antibodi
nearli
equal
obtain
anim
also
show
previous
demonstr
presenc
function
gp
vector
particl
associ
increas
replic
respiratori
tract
spread
beyond
respiratori
tract
guinea
pig
indic
express
function
incorpor
attachmentpenetr
glycoprotein
system
viru
mediat
chang
tissu
tropism
ebola
viru
ebov
caus
sporad
outbreak
sever
hemorrhag
fever
rain
forest
central
africa
nkogh
et
al
lethal
human
speci
zair
bulletin
nkogh
et
al
viru
transmit
contact
infect
patient
fluid
thought
enter
break
skin
inocul
mucos
membran
geisbert
jahrl
jaax
et
al
jaax
et
al
viru
also
demonstr
infect
nonhuman
primat
laboratori
gener
aerosol
consid
potenti
biolog
weapon
salvaggio
baddley
develop
vaccin
ebov
prioriti
two
vector
vaccin
candid
base
human
adenoviru
type
vesicular
stomat
viru
third
candid
base
viruslik
particl
deliv
parenter
shown
protect
nonhuman
primat
jone
et
al
sullivan
et
al
warfield
et
al
interest
gener
issu
develop
vector
direct
immun
respiratori
tract
frequent
portal
infect
highli
pathogen
virus
induct
local
immun
respons
respiratori
tract
would
advantag
prevent
ebov
transmit
contact
respiratori
mucosa
aerosol
previous
develop
intranas
vaccin
candid
ebov
base
human
parainfluenza
viru
type
vector
envelop
rnacontain
viru
famili
paramyxovirida
common
caus
human
pediatr
diseas
karron
collin
genom
singl
negativesens
strand
rna
nt
encod
six
essenti
viral
protein
name
major
nucleocapsid
protein
n
nucleocapsid
phosphoprotein
p
matrix
protein
fusion
glycoprotein
f
hemagglutininneuraminidas
glycoprotein
hn
larg
polymeras
protein
l
also
encod
accessori
c
protein
overlap
open
read
frame
p
gene
genet
evid
express
third
protein
v
replic
primarili
superfici
cell
lumen
respiratori
tract
remain
larg
restrict
site
zhang
et
al
use
revers
genet
one
open
read
frame
encod
foreign
protein
readili
place
control
independ
set
genestart
geneend
transcript
signal
insert
gene
order
skiadopoulo
et
al
infect
induc
system
local
respiratori
tract
immun
respons
use
vector
express
foreign
glycoprotein
direct
inocul
respiratori
tract
guinea
pig
bukreyev
et
al
african
green
monkey
bukreyev
et
al
result
effect
induct
ebovspecif
serum
antibodi
protect
intraperiton
challeng
high
dose
ebov
previous
note
foreign
ebov
gp
glycoprotein
incorpor
ebogp
vector
particl
bukreyev
et
al
furthermor
appear
function
base
observ
vector
partial
lost
sensit
neutral
antibodi
acquir
substanti
sensit
neutral
antiebov
antibodi
bukreyev
et
al
anim
human
ebov
typic
establish
system
infect
result
high
ebov
titer
intern
organ
blood
wherea
contrast
pneumotrop
sinc
ebov
gp
function
attach
penetr
incorpor
vector
particl
potenti
result
alter
tissu
tropism
possibl
increas
replic
vector
respiratori
tract
spread
vector
variou
tissu
beyond
respiratori
tract
present
studi
evalu
possibl
guinea
pig
experiment
anim
permiss
guinea
pigadapt
ebov
bukreyev
et
al
addit
investig
potenti
complic
use
vector
common
human
pathogen
adult
human
popul
substanti
immun
due
prior
natur
exposur
prior
immun
would
expect
restrict
replic
although
effect
might
offset
presenc
function
gp
human
popul
reduct
vector
replic
could
greatli
reduc
immunogen
express
foreign
antigen
problem
would
uniqu
vector
sinc
sever
current
human
vaccin
candid
base
viral
vector
common
human
pathogen
review
bukreyev
et
al
exampl
comparison
immunogen
sever
vaccinia
virusvector
human
adenoviru
type
vaccin
preclin
trial
rodent
nonhuman
primat
clinic
studi
demonstr
preexist
immun
vector
reduc
complet
abolish
immunogen
vaccin
casimiro
et
al
fitzgerald
et
al
kanesathasan
et
al
lemckert
et
al
sharp
et
al
sumida
et
al
zhi
et
al
particular
induct
ebovspecif
cellular
humor
respons
recombin
adenoviru
type
express
ebov
gp
mice
reduc
due
prior
exposur
adenovir
vector
yang
et
al
present
studi
evalu
replic
immunogen
guinea
pig
recent
infect
show
despit
restrict
replic
vaccin
preexist
immun
express
ebov
gp
remain
highli
immunogen
previous
show
express
ebov
gp
glycoprotein
result
function
incorpor
ebov
gp
vector
particl
bukreyev
et
al
potenti
alter
tissu
tropism
confer
increas
pulmonari
replic
spread
viru
beyond
respiratori
tract
evalu
possibl
guinea
pig
experiment
anim
support
moder
level
pulmonari
replic
permiss
system
replic
readili
kill
low
dose
pfu
guinea
pigadapt
ebov
bukreyev
et
al
sinc
adapt
ebov
guinea
pig
requir
mutat
gp
volchkov
et
al
guinea
pig
model
sensit
indic
ebov
gpmediat
pathogen
effect
test
possibl
enhanc
pulmonari
replic
guinea
pig
mockinfect
infect
intranas
rout
tissuecultureinfectiousdos
tcid
day
inocul
anim
sacrif
nasal
turbin
lung
isol
titer
tissu
extract
determin
tcid
titrat
llcmk
cell
monolay
fig
data
show
effici
replic
upper
lower
respiratori
tract
highest
viru
titer
detect
day
somewhat
lower
titer
day
littl
detect
viru
day
compar
viru
replic
similar
slightli
reduc
level
depend
locat
time
point
fig
also
evalu
presenc
viral
antigen
lower
respiratori
tract
immunohistochemistri
guinea
pig
infect
ebogp
sacrif
day
lung
harvest
stain
antigen
polyval
antibodi
rais
sucros
gradientpurifi
fig
anim
viral
antigen
stain
brown
detect
bronchi
bronchiol
extend
inflammatori
alveolar
lesion
virus
moder
amount
antigen
detect
bronchi
fig
b
less
detect
smaller
airway
c
even
less
alveoli
e
f
gener
less
antigen
detect
anim
compar
control
anim
thu
evid
attenu
rather
increas
spread
associ
express
ebov
gp
next
test
possibl
might
spread
tissu
beyond
respiratori
tract
group
seroneg
guinea
pig
inocul
ebogp
two
four
day
inocul
anim
sacrif
sampl
peripher
blood
liver
kidney
spleen
collect
peripher
blood
sampl
tissu
extract
test
presenc
infecti
viru
limit
dilut
assay
describ
viru
detect
sampl
shown
taken
togeth
data
indic
presenc
ebov
gp
vector
particl
confer
enhanc
replic
promot
spread
vector
beyond
respiratori
tract
sinc
incorpor
ebov
gp
protein
recombin
vector
previous
observ
reduc
sensit
neutral
antibodi
vitro
bukreyev
et
al
possibl
would
enhanc
abil
replic
vitro
vivo
presenc
immun
evalu
vitro
infect
replic
cultur
cell
multipl
infect
moi
pfucel
min
adsorpt
period
incub
cultur
medium
contain
dilut
polyval
antiserum
cultur
incub
aliquot
overli
medium
collect
daili
viru
titrat
plaqu
assay
cultur
antiserum
ad
viru
replic
effici
fig
top
cultur
incub
presenc
antiserum
detect
day
low
bare
detect
titer
detect
day
contrast
recov
presenc
antibodi
titer
rang
log
pfuml
fig
bottom
although
titer
much
lower
cell
contain
antibodi
fig
top
confirm
repres
increas
infect
cell
monolay
cell
harvest
day
subject
western
blot
analysi
antiserum
show
absenc
antiserum
medium
abund
level
cellassoci
protein
cultur
infect
either
expect
fig
lane
inclus
antiserum
level
intracellular
protein
dramat
reduc
effect
greater
fig
lane
versu
versu
thu
somewhat
resist
neutral
antiserum
multicycl
infect
either
viru
strongli
inhibit
antibodi
next
test
abil
vaccin
construct
replic
anim
immun
vector
guinea
pig
mockinfect
infect
rout
tcid
serum
sampl
collect
day
later
expect
anim
receiv
develop
strong
antibodi
respons
measur
hemagglutinationinhibit
hai
assay
van
wyke
coelingh
winter
murphi
mockinfect
anim
remain
averag
reciproc
titer
log
log
respect
day
primari
infect
anim
infect
rout
tcid
ebogp
day
second
infect
anim
sacrif
nasal
turbin
lung
isol
titer
tissu
extract
determin
describ
viru
detect
test
day
viru
either
nasal
turbin
lung
data
shown
indic
replic
strongli
restrict
anim
next
evalu
whether
restrict
replic
anim
mediat
humor
cellular
compon
immun
respons
whether
differ
done
measur
restrict
confer
prior
infect
chimer
viru
two
surfac
glycoprotein
hn
f
replac
counterpart
serolog
unrel
replic
vitro
vivo
effici
wild
type
tao
et
al
hn
f
protein
hpiv
antigen
induc
neutral
antibodi
karron
collin
crossprotect
vivo
tao
et
al
thu
immun
induc
would
involv
intern
virion
protein
would
involv
neutral
antibodi
presum
would
primarili
involv
cellular
immun
tao
et
al
caveat
exclud
possibl
intern
protein
might
induc
antibodi
neutral
viru
vitro
might
restrict
replic
vivo
antibodi
describ
sever
virus
includ
rotaviru
burn
et
al
feng
et
al
sindbi
viru
mendoza
stanley
griffin
although
thu
far
guinea
pig
infect
rout
tcid
mockinfect
serum
sampl
collect
day
assay
hai
antibodi
infect
result
reciproc
antibodi
titer
log
wherea
detect
respons
mockinfect
anim
reciproc
titer
log
also
analyz
sera
abil
neutral
use
vitro
plaqu
reduct
assay
show
sera
anim
infect
complet
neutral
incomplet
neutral
previous
describ
introduct
bukreyev
et
al
wherea
neither
viru
neutral
sera
mockimmun
anim
data
shown
thu
expect
specif
confirm
fortytwo
day
primari
infect
challeng
anim
rout
tcid
two
day
second
infect
peak
viral
replic
primari
infect
shown
fig
anim
sacrif
nasal
turbin
lung
analyz
presenc
viru
similar
previou
experi
anim
mockinfect
challeng
equal
high
titer
lung
nasal
turbin
fig
anim
immun
challeng
neither
challeng
viru
detect
either
locat
fig
contrast
anim
immun
challeng
challeng
virus
replic
nasal
turbin
level
approxim
equival
significantli
reduc
compar
anim
initi
mockinfect
lung
immun
anim
detect
low
level
challeng
viru
fig
order
confirm
reduct
titer
anim
authent
vivo
effect
result
neutral
vitro
hpivspecif
antibodi
follow
harvest
tissu
homogen
perform
n
hn
genespecif
quantit
revers
transcript
rt
pcr
assay
use
rna
extract
nasal
turbin
lung
tissu
sampl
assay
threshold
cycl
ct
number
cycl
requir
amplif
sampl
detect
signal
thu
would
low
sampl
high
viral
titer
determin
tcid
assay
would
high
lowtit
sampl
result
n
genespecif
assay
shown
fig
similar
viru
titrat
result
fig
signific
differ
ct
two
challeng
virus
either
immun
group
either
anatom
locat
addit
ct
valu
group
significantli
higher
mock
group
ct
valu
group
significantli
lower
group
greater
although
significantli
mock
group
similar
data
obtain
hn
genespecif
assay
shown
thu
basi
viru
titrat
less
protect
replic
nasal
turbin
wherea
differ
lung
fig
basi
quantit
rtpcr
less
protect
locat
substanti
incomplet
protect
provid
compar
indic
surfac
intern
protein
make
contribut
restrict
regard
intern
protein
exclud
possibl
contribut
antibodi
detect
vitro
neutral
assay
seem
like
cellular
immun
made
major
contribut
effect
addit
find
least
restrict
prior
immun
indic
express
incorpor
foreign
gp
confer
increas
replic
substanti
escap
immun
case
mediat
factor
neutral
antibodi
note
introduct
sever
instanc
experiment
vector
vaccin
preexist
immun
vector
reduc
block
immun
respons
express
foreign
antigen
therefor
compar
abil
induc
serum
antibodi
respons
ebov
gp
guinea
pig
either
possess
lack
prior
immun
follow
experiment
scheme
fig
top
panel
guinea
pig
infect
rout
tcid
tcid
ebogp
mockinfect
serum
sampl
collect
day
infect
fortynin
day
first
infect
anim
receiv
second
infect
rout
tcid
mockinfect
serum
sampl
collect
day
second
infect
serum
sampl
analyz
antibodi
hai
fig
middl
panel
ebovspecif
antibodi
enzymelink
immunoadsorb
assay
elisa
inactiv
disrupt
ebov
bottom
panel
expect
follow
primari
infect
fig
middl
panel
group
group
anim
develop
serum
antibodi
respons
anim
infect
reciproc
titer
antibodi
reach
log
infect
tcid
group
log
infect
tcid
group
comparison
infect
tcid
group
induc
lower
antibodi
titer
log
p
might
reflect
somewhat
reduc
replic
compar
observ
fig
well
possibl
reduct
densiti
hn
protein
surfac
viral
particl
due
incorpor
gp
protein
bukreyev
et
al
event
differ
larg
disappear
time
titer
antibodi
group
receiv
singl
dose
group
nearli
day
follow
day
infect
anim
receiv
singl
dose
group
similar
previou
experi
anim
mockinfect
subsequ
infect
fig
bottom
panel
group
develop
high
titer
serum
antibodi
specif
ebov
base
previou
work
would
associ
complet
protect
challeng
highli
lethal
dose
ebov
bukreyev
et
al
surprisingli
strong
serum
antibodi
respons
ebov
achiev
even
anim
previous
infect
group
ebovspecif
antibodi
titer
achiev
anim
group
slightli
less
achiev
anim
group
day
follow
second
infect
essenti
equival
day
data
indic
despit
restrict
replic
anim
vaccin
construct
highli
immunogen
addit
also
observ
signific
increas
time
titer
ebovspecif
antibodi
anim
receiv
singl
dose
day
group
specif
day
titer
increas
respect
compar
day
thu
respons
increas
rather
decreas
time
threemonth
interv
sinc
ebov
gp
incorpor
particl
possibl
gpspecif
immun
respons
induc
anim
due
preform
gp
contain
inoculum
thu
investig
whether
immun
respons
ebov
gp
depend
replic
immun
four
guinea
pig
rout
tcid
anoth
four
anim
uvinactiv
uv
dose
precalibr
minimum
necessari
inactiv
infect
done
minim
possibl
loss
immunogen
might
result
damag
viral
protein
twentynin
day
inocul
serum
sampl
collect
analyz
presenc
serum
antibodi
specif
ebov
previou
experi
anim
immun
infecti
develop
high
titer
serum
antibodi
specif
ebov
fig
contrast
three
four
anim
immun
uvinactiv
remain
seroneg
remain
anim
low
level
antibodi
titer
regard
ebovspecif
respons
anim
immun
low
level
antibodi
ebov
poor
immunogen
anim
fig
suggest
strong
ebovspecif
respons
anim
fig
depend
replic
even
though
infecti
progeni
viru
detect
nasal
turbin
lung
tissu
fig
howev
also
conceiv
anim
antibodymedi
enhanc
occur
independ
replic
captur
antibodyviru
complex
dendrit
cell
macrophag
investig
infect
mockinfect
group
guinea
pig
rout
tcid
fortytwo
day
later
anim
immun
rout
tcid
equival
amount
ebogp
nonimmun
anim
induc
strong
ebovspecif
antibodi
respons
alreadi
seen
wherea
respons
ebogp
margin
like
fig
differ
immun
nonimmun
anim
data
suggest
preexist
antibodi
enhanc
immunogen
alreadi
note
wherea
infect
superfici
cell
respiratori
tract
typic
spread
significantli
beyond
site
ebov
caus
system
infect
although
detect
spread
viabl
blood
spleen
liver
kidney
follow
inocul
also
import
evalu
whether
system
infect
might
occur
follow
inocul
parenter
rout
test
possibl
infect
six
guinea
pig
rout
six
anim
im
rout
three
anim
im
rout
use
dose
tcid
instanc
thirti
day
immun
serum
sampl
collect
analyz
presenc
antibodi
specif
ebov
comparison
sera
anim
infect
dose
previou
experi
examin
parallel
respons
im
infect
either
viru
readili
detect
margin
reduc
compar
infect
fig
left
panel
surpris
sinc
im
inocul
respiratori
syncyti
viru
previous
shown
induc
titer
neutral
serum
antibodi
onethird
high
titer
induc
infect
appar
reflect
abort
replic
cycl
site
im
inject
princ
et
al
contrast
im
infect
result
low
level
ebovspecif
serum
antibodi
averag
magnitud
log
lower
control
anim
immun
rout
experi
fig
right
panel
reduc
immunogen
given
parenter
interpret
indic
viru
effici
infect
cell
effici
replic
follow
parenter
administr
substanti
respons
specif
hn
detect
hai
assay
may
reflect
unusu
high
immunogen
protein
lack
signific
ebovspecif
respons
follow
im
infect
support
idea
reduc
rather
increas
capabl
replic
system
also
consist
idea
amount
protein
contain
inoculum
insuffici
significantli
immunogen
naiv
anim
studi
evalu
safeti
replic
immunogen
intranas
vaccin
ebov
guinea
pig
presenc
absenc
prior
immun
vector
administ
nonimmun
anim
high
level
viru
replic
occur
result
robust
serum
antibodi
respons
vector
insert
anim
challeng
ebov
particular
studi
sinc
previous
demonstr
level
ebovspecif
antibodi
associ
uniform
protect
highli
lethal
dose
ebov
bukreyev
et
al
present
studi
also
show
pulmonari
replic
slightli
reduc
compar
parent
infecti
viru
could
detect
peripher
blood
liver
kidney
spleen
addit
parenter
inocul
induc
signific
level
serum
antibodi
ebov
thu
even
though
ebov
gp
incorpor
vector
particl
confer
resist
antibodi
sensit
ebovspecif
antibodi
evid
function
initi
infect
result
increas
pulmonari
replic
confer
abil
spread
replic
detect
peripher
tissu
noteworthi
sinc
ebov
gp
mediat
viral
attach
entri
thu
would
potenti
alter
tropism
guinea
pig
highli
permiss
replic
guinea
pigadapt
ebov
note
requir
mutat
gp
sensit
virusinduc
diseas
death
thu
provid
sensit
test
increas
pathogen
due
ebov
gp
find
form
preced
gener
use
relev
regard
issu
biolog
safeti
recombin
vector
express
foreign
surfac
protein
incorpor
protein
vector
particl
administ
anim
infecti
viru
could
detect
nasal
turbin
lung
tissu
harvest
day
follow
infect
restrict
replic
mediat
antibodi
cellular
compon
immun
respons
determin
use
anim
immun
chimer
viru
express
intern
protein
surfac
neutral
antigen
surprisingli
despit
lack
detect
replic
respiratori
tract
immunogen
essenti
observ
anim
suffici
protect
ebov
challeng
bukreyev
et
al
one
caveat
directli
measur
cellmedi
respons
anim
due
lack
avail
reagent
therefor
rule
formal
possibl
cellular
immun
respons
substanti
reduc
anim
howev
even
without
contribut
cellmedi
immun
level
ebovspecif
serum
antibodi
achiev
would
consist
substanti
protect
present
studi
mean
reciproc
elisa
titer
ebovspecif
serum
antibodi
approxim
day
day
previou
studi
show
passiv
ebovspecif
antibodi
alon
provid
substanti
protect
ebov
challeng
one
studi
guinea
pig
infect
intraperiton
ebov
immedi
given
ebovspecif
passiv
antibodi
subcutan
rout
dose
antibodi
confer
serum
elisa
titer
measur
two
day
later
provid
complet
protect
day
infect
pfu
guinea
pigadapt
ebov
jahrl
et
al
compar
experi
mice
dose
antibodi
confer
serum
elisa
titer
approxim
measur
day
provid
high
level
protect
day
challeng
pfu
ebov
gupta
et
al
suggest
respons
achiev
anim
present
studi
would
protect
data
contrast
studi
involv
vector
system
immunogen
human
adenoviru
type
vaccinia
virusvector
vaccin
significantli
reduc
complet
abolish
presenc
vectorspecif
immun
see
introduct
mechan
immunogen
latter
vector
reduc
immun
anim
unknown
might
includ
neutral
vector
inoculum
rapid
destruct
vectorinfect
cell
neutral
progeni
vector
case
replicationcompet
vector
sever
mechan
retain
immunogen
anim
suggest
one
possibl
presenc
function
ebov
gp
vector
particl
confer
increas
infect
spread
anim
monolay
cell
cultur
found
inde
resist
neutral
antibodi
somewhat
greater
abil
spread
condit
although
effect
modest
condit
test
vitro
might
suffici
confer
increas
immunogen
vivo
addit
rout
administr
might
play
role
abil
immun
despit
preexist
immun
vector
specif
effect
host
immun
respiratori
tract
characterist
incomplet
due
shortliv
natur
mucos
immun
follow
primari
infect
ineffici
serum
antibodi
gain
access
respiratori
lumen
function
impair
cytotox
lymphocyt
lung
vallbracht
unsold
ehl
addit
certain
respiratori
virus
hpiv
respiratori
syncyti
viru
seem
particularli
abl
partial
evad
host
immun
establish
symptomat
reinfect
wherea
respiratori
virus
influenza
viru
adenoviru
strongli
restrict
prior
immun
although
basi
behind
reinfect
virus
poorli
understood
may
contribut
effect
observ
recent
studi
show
cotton
rat
immun
respiratori
syncyti
viru
reinfect
viru
level
intracellular
viral
rna
synthesi
first
h
infect
nearli
high
nonimmun
anim
even
though
infecti
progeni
viru
detect
immun
anim
throughout
infect
boukhvalova
princ
blanco
thu
prior
immun
seem
restrict
infect
initi
viral
replic
cycl
presum
would
result
substanti
antigen
synthesi
context
noteworthi
recent
studi
demonstr
activ
respiratori
dendrit
cell
take
place
within
first
h
infect
mice
influenza
viru
legg
bracial
long
peak
viru
replic
lung
respiratori
dendrit
cell
becom
refractori
stimul
viru
legg
bracial
therefor
effect
present
ebov
antigen
may
depend
initi
infect
initi
replic
cycl
viru
less
depend
magnitud
subsequ
replic
previous
assum
vector
would
suffici
immunogen
adolesc
adult
due
preval
immun
common
human
pathogen
howev
present
studi
suggest
use
pneumotrop
vector
topic
rout
immun
may
provid
substanti
immun
immun
individu
inde
vector
restrict
host
immun
nonetheless
immunogen
vaccin
safeti
would
increas
howev
essenti
confirm
immunogen
nonhuman
primat
anatom
phylogenet
close
relat
human
would
follow
clinic
trial
interest
safeti
would
employ
attenu
version
vector
sever
attenu
version
present
clinic
trial
pediatr
intranas
vaccin
candid
sinc
nonhuman
primat
less
permiss
human
replic
result
obtain
nonhuman
primat
use
wild
type
vector
may
compar
would
observ
human
use
attenu
deriv
vector
also
develop
chimer
virus
hn
f
protein
vector
delet
replac
gp
would
provid
vector
would
neutral
antibodi
major
hn
f
antigen
chimer
viru
would
remain
sensit
cellular
immun
direct
intern
protein
immun
compon
much
less
longliv
neutral
antibodi
like
would
less
effect
restrict
vector
final
use
nonhuman
respiratori
paramyxovirus
newcastl
diseas
viru
platform
intranas
vaccin
ebov
may
also
promis
approach
recombin
wild
type
use
studi
describ
previous
bukreyev
et
al
durbin
et
al
uvinactiv
perform
uv
stratalink
stratagen
la
jolla
ca
use
uv
dose
mjoul
determin
minimum
dose
requir
complet
inactiv
infect
prepar
rhesu
monkey
kidney
human
type
ii
alveolar
adenocarcinoma
cell
american
type
cultur
collect
manassa
va
grown
optimem
medium
contain
fetal
bovin
serum
invitrogen
carlsbad
ca
grown
titrat
cell
guinea
pig
strain
hartley
four
thirteen
week
old
obtain
charl
river
laboratori
wilmington
confirm
seroneg
hai
use
guinea
pig
erythrocyt
van
wyke
coelingh
winter
murphi
intranas
inocul
anim
anesthet
inhal
methoxyfluran
medic
develop
intern
limit
springval
australia
viral
suspens
leibowitz
medium
invitrogen
appli
nostril
intramuscular
im
inocul
involv
viral
suspens
medium
per
anim
isol
intern
organ
tissu
sampl
anim
sacrif
carbon
dioxid
inhal
procedur
perform
accord
protocol
guidelin
approv
nih
anim
care
use
committe
perform
facil
approv
associ
assess
accredit
laboratori
anim
care
intern
polyval
antiserum
prepar
hyperimmun
rabbit
sucros
gradientpurifi
harvest
tissu
weigh
homogen
medium
invitrogen
use
omni
th
tissu
homogen
dispos
tip
omni
intern
marietta
ga
clarifi
lowspe
centrifug
result
tissu
suspens
aliquot
store
viru
titrat
viru
titer
determin
limit
dilut
cell
express
tcid
case
plaqu
titrat
cell
also
perform
previous
describ
bukreyev
et
al
quantit
rtpcr
total
rna
isol
tissu
extract
use
rneasi
mini
kit
qiagen
valencia
ca
accord
manufactur
recommend
subject
revers
transcript
reaction
random
hexam
analyz
taqman
gene
express
assay
appli
biosystem
foster
citi
ca
follow
set
primer
probe
design
produc
appli
biosystem
n
genespecif
set
forward
primer
revers
primer
probe
hnspecif
set
forward
primer
revers
primer
probe
case
nasal
turbin
lung
sampl
anim
neg
viral
rna
due
high
level
protect
sampl
assign
ct
valu
limit
detect
order
calcul
mean
ct
se
lung
tissu
fix
neutral
buffer
formalin
embed
paraffin
section
cut
micron
section
mount
posit
charg
slide
antigen
retriev
paraffin
section
perform
food
steamer
sunbeam
boca
raton
fl
diva
decloak
solut
biocar
concord
ca
immunostain
antigen
perform
use
dilut
polyclon
antibodi
dako
envis
rabbit
hrp
dab
kit
hrp
label
polym
dako
carpenteria
ca
serum
antibodi
respons
determin
abovement
hai
assay
van
wyke
coelingh
winter
murphi
ebovspecif
serum
antibodi
respons
determin
elisa
ebov
particl
inactiv
gamma
radiat
purifi
disrupt
tween
bukreyev
et
al
fig
assay
perform
exactli
previous
describ
bukreyev
et
al
fig
assay
perform
essenti
way
differ
plate
wash
solut
secondari
antibodi
detect
chemistri
specif
ebov
antigen
coat
onto
flat
bottom
immulux
hb
plate
dynex
technolog
chantilli
va
coat
plate
wash
five
time
phosphat
buffer
salin
invitrogen
contain
pbst
incub
h
block
buffer
compos
phosphat
buffer
salin
nonfat
dri
milk
nestl
solon
oh
bovin
serum
albumin
fraction
v
roch
usa
indianapoli
wash
variou
dilut
guinea
pig
serum
sampl
block
buffer
ad
plate
incub
h
wash
next
dilut
alkalin
phosphataseconjug
goat
antiguinea
pig
igg
antibodi
antibodi
incorpor
davi
ca
block
buffer
ad
incub
h
wash
develop
plate
per
well
alkalin
phosphatas
yellow
pnpp
liquid
substrat
system
elisa
sigmaaldrich
st
loui
mo
ad
plate
incub
min
room
temperatur
reaction
stop
ad
per
well
n
sodium
hydroxid
optic
densiti
determin
nm
differ
evalu
student
ttest
consid
signific
p
data
shown
mean
se
mean
replic
nasal
turbin
top
panel
lung
bottom
panel
guinea
pig
anim
infect
intranas
rout
tcid
anim
sacrif
day
five
anim
per
group
six
anim
per
group
five
anim
per
group
inocul
nasal
turbin
lung
isol
viru
titer
determin
mean
valu
shown
se
p
valu
indic
top
limit
detect
shown
arrow
log
tcid
ml
nasal
turbin
lung
respect
viru
detect
individu
anim
valu
onehalf
limit
detect
assign
purpos
calcul
replic
cell
presenc
antibodi
specif
cell
monolay
infect
input
moi
pfucel
subsequ
incub
perform
presenc
absenc
neutral
polyval
antibodi
analysi
infecti
viru
product
aliquot
medium
collect
daili
viral
titer
determin
plaqu
titrat
b
analysi
intracellular
viral
protein
indic
viru
replic
cell
collect
day
post
infect
total
protein
subject
western
blot
analysi
polyval
antiserum
equal
amount
cell
lysat
load
gel
day
infect
monolay
antibodi
complet
destroy
virus
therefor
analyz
two
band
correspond
protein
p
n
shown
lane
magic
mark
xp
protein
marker
band
correspond
kda
kda
cell
replic
nasal
turbin
left
panel
lung
right
panel
guinea
pig
previous
mockinfect
infect
indic
initi
infect
dose
tcid
second
infect
day
later
dose
tcid
anim
four
per
viru
per
day
sacrif
day
later
nasal
turbin
lung
isol
use
viru
titrat
b
isol
total
rna
comparison
viral
rna
concentr
quantit
rtpcr
part
limit
detect
fig
indic
arrow
valu
repres
mean
viral
titer
b
mean
threshold
concentr
ct
se
p
valu
indic
top
quantit
rtpcr
rna
lung
anim
three
rather
four
anim
analyz
second
infect
group
contain
anim
group
includ
anim
day
antibodi
titer
group
detect
limit
hai
assay
log
indic
asterisk
effect
replic
rout
immun
immunogen
effect
replic
guinea
pig
four
anim
per
group
infect
ebogp
dose
tcid
equival
amount
uvinactiv
viru
sera
collect
day
postinfect
titer
ebovspecif
serum
antibodi
determin
hai
elisa
respect
serum
antibodi
titer
express
reciproc
log
endpoint
dilut
shown
mean
titer
se
p
valu
indic
top
sera
mockinfect
anim
repres
anim
separ
experi
level
antibodi
detect
level
log
indic
asterisk
group
level
antibodi
three
four
anim
detect
level
valu
log
assign
calcul
purpos
detect
limit
hai
assay
log
b
effect
versu
im
rout
immun
guinea
pig
immun
tcid
im
rout
six
anim
per
group
tcid
im
rout
three
anim
sera
collect
day
immun
titer
ebovspecif
serum
antibodi
determin
addit
sera
nine
anim
collect
day
infect
tcid
previou
experi
fig
analyz
parallel
comparison
uninfect
group
consist
two
anim
separ
experi
level
antibodi
detect
level
shown
asterisk
group
level
ebovspecif
antibodi
detect
level
shown
plu
detect
limit
hai
assay
log
